← Leaderboards
Mercedes Gonzalez-Juarrero
Colorado State University
$6,903,366
Attributed
$15,370,435
Total exposure
11
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2007–25$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,370,435 · 11
By mechanism
R01$12,517,388 · 5
R21$1,296,828 · 3
S10$889,153 · 2
R56$667,066 · 1
Top collaborators
- Bernd Meibohm12 shared
- Anthony James Hickey7 shared
- Mary Jackson6 shared
- Miriam S. Braunstein5 shared
- Sara Elizabeth Maloney5 shared
- Pallavi Ghosh1 shared
- Anil Kumar Ojha1 shared
Most similar at Colorado State University
Same institution · by research overlap
- Sara Elizabeth Maloney$2,164,235
- Mary Jackson$25,157,631
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionUniversitiesColoradoResearch PersonnelMycobacterium TuberculosisAnimal ModelPharmaceutical PreparationsLungIn VivoIn VitroResistanceGenus MycobacteriumChronicTissuesTuberculosisResponseRegimenDoseAerosolsLung InfectionsRouteSafetyLaboratoriesPharmacotherapy
Grant awards (27)
Inhalational therapy with spectinamides within new regimens of TB therapy$788,086
R01 · FY2025 · AI · contact PI
Therapeutic potential of mycobacteriophage LysB against Mycobacterium abscessus infections$689,051
R01 · FY2025 · AI
Tailoring modifications of polysaccharides in Mycobacterium tuberculosis$637,594
R01 · FY2025 · AI
Inhaled tigecycline therapy for pulmonary M. abscessus infections$623,786
R01 · FY2025 · AI · contact PI
Inhalational therapy with spectinamides within new regimens of TB therapy$817,405
R01 · FY2024 · AI · contact PI
Tailoring modifications of polysaccharides in Mycobacterium tuberculosis$637,594
R01 · FY2024 · AI
Inhaled tigecycline therapy for pulmonary M. abscessus infections$627,834
R01 · FY2024 · AI · contact PI
Inhaled tigecycline therapy for pulmonary M. abscessus infections$691,193
R01 · FY2023 · AI · contact PI
Tailoring modifications of polysaccharides in Mycobacterium tuberculosis$637,594
R01 · FY2023 · AI
Inhaled tigecycline therapy for pulmonary M. abscessus infections$794,098
R01 · FY2022 · AI · contact PI
Tailoring modifications of polysaccharides in Mycobacterium tuberculosis$637,594
R01 · FY2022 · AI
Inhaled tigecycline therapy for pulmonary M. abscessus infections$836,428
R01 · FY2021 · AI · contact PI
Tailoring modifications of polysaccharides in Mycobacterium tuberculosis$511,685
R01 · FY2021 · AI
Vectra Polaris microscope imaging system$451,750
S10 · FY2021 · OD · contact PI
Aerosol spectinamide-1599 therapy against tuberculosis$710,674
R01 · FY2020 · AI · contact PI
Tailoring modifications of polysaccharides in Mycobacterium tuberculosis$667,066
R56 · FY2020 · AI
Aerosol spectinamide-1599 therapy against tuberculosis$729,832
R01 · FY2019 · AI · contact PI
Aerosol spectinamide-1599 therapy against tuberculosis$668,501
R01 · FY2018 · AI · contact PI
Aerosol spectinamide-1599 therapy against tuberculosis$848,545
R01 · FY2017 · AI · contact PI
Aerosol spectinamide-1599 therapy against tuberculosis$629,894
R01 · FY2016 · AI · contact PI
siRNA-nanoparticles host targeted immunotherapy for tuberculosis$187,395
R21 · FY2015 · AI · contact PI
Minipigs as animal model for infant TB and vaccine efficacy$185,875
R21 · FY2015 · AI · contact PI
Minipigs as animal model for infant TB and vaccine efficacy$284,329
R21 · FY2014 · AI · contact PI
siRNA-nanoparticles host targeted immunotherapy for tuberculosis$237,777
R21 · FY2014 · AI · contact PI
Host targeted immunotherapy for TB treatment$192,202
R21 · FY2013 · AI · contact PI
Host targeted immunotherapy for TB treatment$209,250
R21 · FY2012 · AI · contact PI
Zeiss LSM 510 Laser Scanning Microscope$437,403
S10 · FY2007 · RR · contact PI